R&D channel feed – Endpoints News

R&D channel feed

Sarepta halts its golodirsen Duchenne MD study in UK after patient experiences adverse event

8 years ago

Seattle Genetics seeds a new immuno-oncology collaboration with the protein explorers at Pieris

8 years ago

Scientists toss another Alzheimer’s program into the scrap heap as PhII fails

8 years ago

Madrigal touts a mid-stage success in HeFH, cutting bad cholesterol in a competitive field

8 years ago

No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging

8 years ago

Sanofi sounds taps on a half dozen drug programs in latest pipeline cleanup

8 years ago

Biogen scuttles a Tysabri program after the drug fails stroke test, thinning the pipeline

8 years ago

Array MEK/BRAF combo beats out Roche rival in PhIII melanoma OS showdown

8 years ago

Eyeing a blockbuster migraine market, Allergan takes an inside track on acute cases with positive PhIII

8 years ago

Looking to grow blockbuster Pomalyst franchise, Celgene declares a win for multiple myeloma triplet in pivotal PhIII

8 years ago

Roche hails another PhIII win on Tecentriq combo, reports promising kidney cancer data

8 years ago

Pfizer vs J&J: Researchers are duking it out for the championship title in nonmetastatic prostate cancer

8 years ago

Bristol-Myers offers some eagerly awaited Checkmate-227 results, but they're not changing medical practice -- yet

8 years ago

Stock plummets at EyeGate following Phase IIb flop for cataract surgery

8 years ago

As controversy over childhood deaths simmers in the Philippines, Sanofi balks at a Dengvaxia reimbursement

8 years ago

Skeptics pounce after Bristol-Myers scores an early hit on Opdivo-Yervoy combo for lung cancer

8 years ago

AstraZeneca sweeps out a PhIII asthma flop, a PD-1 drug and some other rejects as Q4 tally disappoints

8 years ago

Think your odds of R&D success are miserable? MIT’s Andrew Lo might have a surprise for you

8 years ago

Puma touts its latest advances in a basket trial for Nerlynx, as Europeans appear ready to reject the drug

8 years ago

Roche silently scraps two one-time blockbuster hopefuls as $725M Seragon deal craters

8 years ago

Vertex execs whip up a cheer from the analysts after hedging their bet by picking their two top triples for PhIII

8 years ago

Analysis: Pfizer tallies an impressive array of late-stage catalysts for cancer, gene therapies and more

8 years ago

Focused on blockbuster indications, Sage touts evidence that 217 could work on insomnia

8 years ago

Brain damage cases force an FDA hold on Bellicum's lead cell therapy -- shares tank

8 years ago

First page Previous page 280 281 282283284 285 286 Next page Last page